Cowealth Medical China Co (SHSE:603122) Research & Development: ¥4.0 Mil (TTM As of Mar. 2026)


SHSE:603122 Cowealth Medical China Co Ltd SHSE:603122
41 GF Score
Price ¥11.48
GF Value ¥3.88
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cowealth Medical China Co Research & Development?

Cowealth Medical China Co SHSE:603122 -1.12% 41 Research & Development is ¥4.0 Mil as of Mar. 2026. GuruFocus rates SHSE:603122 with a GF Score™ of 41/100 and a GF Value™ of ¥3.88 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cowealth Medical China Co's Research & Development for the three months ended in Mar. 2026 was ¥0.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥4.0 Mil.

Cowealth Medical China Co  (SHSE:603122) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cowealth Medical China Co Research & Development Related Terms

Cowealth Medical China Co Research & Development Historical Data

* Premium members only.

The historical data trend for Cowealth Medical China Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cowealth Medical China Co Research & Development Chart

Cowealth Medical China Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.00 2.80 3.18 3.75 3.81

Cowealth Medical China Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 1.40 0.53 1.25 0.82
SHSE:603122
41GF Score
Cowealth Medical China Co Ltd SHSE:603122
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cowealth Medical China Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥4.0 Mil mean?
Cowealth Medical China Co (SHSE:603122) has a Research & Development of ¥4.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cowealth Medical China Co and its competitors.
Is Cowealth Medical China Co's Research & Development too high?
Cowealth Medical China Co's current Research & Development is ¥4.0 Mil. Overall, Cowealth Medical China Co has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical China Co's Research & Development compare to TMO and DHR?
Cowealth Medical China Co's Research & Development of ¥4.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cowealth Medical China Co and its competitors. Cowealth Medical China Co's current Research & Development is ¥4.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical China Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical China Co (SHSE:603122) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.88, compared to a current price of ¥11.48 — trading 195.9% above its estimated fair value. The current Research & Development is ¥4.0 Mil. Cowealth Medical China Co's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cowealth Medical China Co (SHSE:603122), the current Research & Development is ¥4.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cowealth Medical China Co (SHSE:603122) Overvalued in 2026?

Based on GuruFocus' analysis, Cowealth Medical China Co stock appears to be overvalued. The current stock price of ¥11.48 is trading 195.9% above its estimated GF Value™ of ¥3.88. GuruFocus considers Cowealth Medical China Co to be Significantly Overvalued.

Key valuation signals for SHSE:603122:

  • Research & Development: ¥4.0 Mil
  • GF Value™: ¥3.88 vs. price of ¥11.48 (195.9% above fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the SHSE:603122 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cowealth Medical China Co Business Description

Address No. 1001 Qinzhou North Road, 21st Floor, Building 12, Xuhui District, Shanghai, CHN, 200131
Cowealth Medical China Co Ltd operates as a diagnostic clinical laboratory company. It has introduced radiation oncology technology into the market.
41GF Score

Get the complete analysis for SHSE:603122

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.48
Price
¥3.88
GF Value